GSE66824

Genomic and Clinical Effects Associated with a Relaxation Response Mind-Body Intervention in Patients with Irritable Bowel Syndrome and Inflammatory Bowel Disease

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

38 case / 14 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Patients with chronic illnesses such as Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) often have reduced quality of life. IBS is characterized by abdominal pain/discomfort associated with altered bowel function, such as diarrhea or constipation, without gross structural changes or inflammation [1]; IBD is characterized by gross inflammation in the gastrointestinal (GI) tract which can result in symptoms such as abdominal pain, cramping, diarrhea and bloody stools. IBS and IBD can profoundly affect quality of life and are influenced by stress and resiliency.The impact of mind-body interventions (MBIs) on IBS and IBD patients has not previously been examined. In this study IBS and IBD patients were enrolled in a 9-week relaxation response based mind-body group intervention (RR-MBI), focusing on elicitation of the RR and cognitive skill building. We performed Peripheral blood transcriptome analysis to identify genomic correlates of the RR-MBI.

Overall design

This pilot, single center, single-arm, open-label study utilized an RR-MBI for the treatment of IBS and IBD using elicitation of the RR through meditation techniques and cognitive skill building, as established by the Benson-Henry Institute for Mind Body Medicine at the Massachusetts General Hospital (BHI).Blood was collected at baseline and after 9 weeks for transcriptional expression profiling in PAXgene (Qiagen) tubes. Total RNA was isolated from whole blood samples and gene expression profile was assessed on IBS and IBD patients with paired pre- and post-intervention samples using HT U133 Plus PM Array plates (Affymetrix, Santa Clara, CA).

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
66 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

2 linked publications 2 DOIs

Primary publication

  1. Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease. PloS one, 2015

Related publications

  1. Genomic Research for Abdominal Pain in Patients with Irritable Bowel Syndrome or Inflammatory Bowel Disease Before and After Mind-Body Intervention. Journal of pain research, 2026
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 14 samples are still unassigned.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

0 review-needed samples and 14 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples are unassigned and need manual grouping decisions.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Inflammatory bowel disease Disease context came from Normalization rules.
  • Likely case group Inflammatory bowel disease 38 samples
  • Likely control group Untreated 14 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biofluid. Comparison suitability: 0%.
  • Interpreted disease metadata: Inflammatory bowel disease.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 2 publications; 2 DOIs available: PMID 25927528, PMID 42299241.
  • Publication context: Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease.. PloS one, 2015. PMID 25927528. DOI 10.1371/journal.pone.0123861.
  • Publication context: Genomic Research for Abdominal Pain in Patients with Irritable Bowel Syndrome or Inflammatory Bowel Disease Before and After Mind-Body Intervention.. Journal of pain research, 2026. PMID 42299241. DOI 10.2147/JPR.S605236.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

254 fields

Sample Group Preview

66 rows shown
Show Hide
Study totals: Case 38 | Control 14 | Unassigned 14 | Excluded 0 | Ambiguous 0 66 rows shown
Group Role Accession Title Source / characteristics Reason
Inflammatory bowel disease Case GSM1632731 Patient B01, IBD, Before Intervention Peripheral blood Patient: B01; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632732 Patient B01, IBD, After 9 weeks of Intervention Peripheral blood Patient: B01; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632733 Patient B03, IBD, Before Intervention Peripheral blood Patient: B03; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632734 Patient B03, IBD, After 9 weeks of Intervention Peripheral blood Patient: B03; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632735 Patient B04, IBD, Before Intervention Peripheral blood Patient: B04; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632736 Patient B04, IBD, After 9 weeks of Intervention Peripheral blood Patient: B04; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632737 Patient B06, IBD, Before Intervention Peripheral blood Patient: B06; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632738 Patient B06, IBD, After 9 weeks of Intervention Peripheral blood Patient: B06; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632739 Patient B07, IBD, Before Intervention Peripheral blood Patient: B07; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632740 Patient B07, IBD, After 9 weeks of Intervention Peripheral blood Patient: B07; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632741 Patient B08, IBD, Before Intervention Peripheral blood Patient: B08; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632742 Patient B08, IBD, After 9 weeks of Intervention Peripheral blood Patient: B08; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632743 Patient B09, IBD, Before Intervention Peripheral blood Patient: B09; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632744 Patient B09, IBD, After 9 weeks of Intervention Peripheral blood Patient: B09; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632745 Patient B11, IBD, Before Intervention Peripheral blood Patient: B11; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632746 Patient B11, IBD, After 9 weeks of Intervention Peripheral blood Patient: B11; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632747 Patient B12, IBD, Before Intervention Peripheral blood Patient: B12; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632748 Patient B12, IBD, After 9 weeks of Intervention Peripheral blood Patient: B12; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632749 Patient B13, IBD, Before Intervention Peripheral blood Patient: B13; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632750 Patient B13, IBD, After 9 weeks of Intervention Peripheral blood Patient: B13; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632751 Patient B14, IBD, Before Intervention Peripheral blood Patient: B14; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632752 Patient B14, IBD, After 9 weeks of Intervention Peripheral blood Patient: B14; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632753 Patient B16, IBD, Before Intervention Peripheral blood Patient: B16; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632754 Patient B16, IBD, After 9 weeks of Intervention Peripheral blood Patient: B16; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632755 Patient B20, IBD, Before Intervention Peripheral blood Patient: B20; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632756 Patient B20, IBD, After 9 weeks of Intervention Peripheral blood Patient: B20; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632757 Patient B22, IBD, Before Intervention Peripheral blood Patient: B22; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632758 Patient B22, IBD, After 9 weeks of Intervention Peripheral blood Patient: B22; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632759 Patient B23, IBD, Before Intervention Peripheral blood Patient: B23; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632760 Patient B23, IBD, After 9 weeks of Intervention Peripheral blood Patient: B23; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632761 Patient B24, IBD, Before Intervention Peripheral blood Patient: B24; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632762 Patient B24, IBD, After 9 weeks of Intervention Peripheral blood Patient: B24; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632763 Patient B25, IBD, Before Intervention Peripheral blood Patient: B25; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632764 Patient B25, IBD, After 9 weeks of Intervention Peripheral blood Patient: B25; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632765 Patient B29, IBD, Before Intervention Peripheral blood Patient: B29; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632766 Patient B29, IBD, After 9 weeks of Intervention Peripheral blood Patient: B29; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632767 Patient B30, IBD, Before Intervention Peripheral blood Patient: B30; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: Before intervention; Tissue: Peripheral blood Case marker detected.
Inflammatory bowel disease Case GSM1632768 Patient B30, IBD, After 9 weeks of Intervention Peripheral blood Patient: B30; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBD; Time point: After 9 weeks of intervention; Tissue: Peripheral blood Case marker detected.
Untreated Control GSM1632703 Patient A01, IBS, Baseline Before Intervention Peripheral blood Patient: A01; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632705 Patient A02, IBS, Baseline Before Intervention Peripheral blood Patient: A02; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632707 Patient A03, IBS, Baseline Before Intervention Peripheral blood Patient: A03; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632709 Patient A06, IBS, Baseline Before Intervention Peripheral blood Patient: A06; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632711 Patient A07, IBS, Baseline Before Intervention Peripheral blood Patient: A07; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632713 Patient A10, IBS, Baseline Before Intervention Peripheral blood Patient: A10; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632715 Patient A13, IBS, Baseline Before Intervention Peripheral blood Patient: A13; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632717 Patient A14, IBS, Baseline Before Intervention Peripheral blood Patient: A14; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632719 Patient A15, IBS, Baseline Before Intervention Peripheral blood Patient: A15; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632721 Patient A16, IBS, Baseline Before Intervention Peripheral blood Patient: A16; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632723 Patient A18, IBS, Baseline Before Intervention Peripheral blood Patient: A18; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632725 Patient A20, IBS, Baseline Before Intervention Peripheral blood Patient: A20; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632727 Patient A23, IBS, Baseline Before Intervention Peripheral blood Patient: A23; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Untreated Control GSM1632729 Patient A25, IBS, Baseline Before Intervention Peripheral blood Patient: A25; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: Baseline before intervention; Tissue: Peripheral blood Treatment control marker detected.
Unassigned Unassigned GSM1632704 Patient A01, IBS, After 9 weeks of Intervention Peripheral blood Patient: A01; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632706 Patient A02, IBS, After 9 weeks of Intervention Peripheral blood Patient: A02; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632708 Patient A03, IBS, After 9 weeks of Intervention Peripheral blood Patient: A03; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632710 Patient A06, IBS, After 9 weeks of Intervention Peripheral blood Patient: A06; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632712 Patient A07, IBS, After 9 weeks of Intervention Peripheral blood Patient: A07; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632714 Patient A10, IBS, After 9 weeks of Intervention Peripheral blood Patient: A10; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632716 Patient A13, IBS, After 9 weeks of Intervention Peripheral blood Patient: A13; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632718 Patient A14, IBS, After 9 weeks of Intervention Peripheral blood Patient: A14; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632720 Patient A15, IBS, After 9 weeks of Intervention Peripheral blood Patient: A15; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632722 Patient A16, IBS, After 9 weeks of Intervention Peripheral blood Patient: A16; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632724 Patient A18, IBS, After 9 weeks of Intervention Peripheral blood Patient: A18; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632726 Patient A20, IBS, After 9 weeks of Intervention Peripheral blood Patient: A20; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632728 Patient A23, IBS, After 9 weeks of Intervention Peripheral blood Patient: A23; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.
Unassigned Unassigned GSM1632730 Patient A25, IBS, After 9 weeks of Intervention Peripheral blood Patient: A25; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood; Disease state: IBS; Time point: After 9 weeks of intervention; Tissue: Peripheral blood No explicit case or control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.